377 related articles for article (PubMed ID: 25772644)
1. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
[TBL] [Abstract][Full Text] [Related]
2. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?
Jean SS; Hsieh TC; Lee WS; Hsueh PR; Hsu CW; Lam C
Medicine (Baltimore); 2018 Sep; 97(39):e12278. PubMed ID: 30278498
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
6. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.
Nazer LH; Rihani S; Hawari FI; Le J
Infect Dis (Lond); 2015; 47(11):755-60. PubMed ID: 26050703
[TBL] [Abstract][Full Text] [Related]
7. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
10. Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization.
Hsieh TC; Chen FL; Ou TY; Jean SS; Lee WS
J Microbiol Immunol Infect; 2016 Aug; 49(4):523-30. PubMed ID: 25442877
[TBL] [Abstract][Full Text] [Related]
11. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?
Kalin G; Alp E; Coskun R; Demiraslan H; Gündogan K; Doganay M
J Infect Chemother; 2012 Dec; 18(6):872-7. PubMed ID: 22644081
[TBL] [Abstract][Full Text] [Related]
12. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
Li KL; Abad CLR
Int J Infect Dis; 2020 Apr; 93():9-14. PubMed ID: 31978579
[TBL] [Abstract][Full Text] [Related]
13. Prospective observational study of the impact of plasma colistin levels in patients with carbapenem-resistant Acinetobacter baumannii pneumonia.
Jeong YJ; Gu N; Kwack WG; Kang Y; Park SY; Yoon YS
J Glob Antimicrob Resist; 2021 Dec; 27():315-323. PubMed ID: 34775134
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
16. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Chiang SR; Chuang YC; Tang HJ; Chen CC; Chen CH; Lee NY; Chou CH; Ko WC
Crit Care Med; 2009 Sep; 37(9):2590-5. PubMed ID: 19623044
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
19. Outcome analysis of colistin-treated burn center patients.
Wilkinson RE; Hill DM; Hickerson WL
Burns; 2017 Sep; 43(6):1244-1249. PubMed ID: 28410932
[TBL] [Abstract][Full Text] [Related]
20. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections.
Sadyrbaeva-Dolgova S; García-Fumero R; Exposito-Ruiz M; Pasquau-Liaño J; Jiménez-Morales A; Hidalgo-Tenorio C
Sci Rep; 2022 Sep; 12(1):15261. PubMed ID: 36088407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
